Entrada Therapeutics price target lowered to $23 from $29 at Roth MKM
Roth MKM analyst Boobalan Pachaiyappan lowered the firm’s price target on Entrada Therapeutics (TRDA) to $23 from $29 and keeps a Buy rating on ...
Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA), Viridian Therapeutics (VRDN) and Definitive Healthcare Corp (DH)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Entrada Therapeutics Inc (TRDA – Research ...
MM&M11h
Rx Rundown: Thermo Fisher Scientific, the CDC, Eli Lilly and more
Rare Disease Day, an annual gathering hosted by the FDA and National Institutes of Health, was postponed. Medicare spending on 10 diabetes drugs, including popular GLP-1s, more than quadrupled over a ...
Managed Healthcare Executive9h
Duchenne Muscular Dystrophy: The Brain Is Affected Too
Researchers, physicians, families and affected patients view Duchenne muscular dystrophy (DMD) as a neuromuscular condition. Children are diagnosed during the first years of life because they have ...